These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 10606256)

  • 41. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
    Benson AB
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Mitry E; Ducreux M; Rougier P
    Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topoisomerase I inhibitors for the treatment of brain tumors.
    Feun L; Savaraj N
    Expert Rev Anticancer Ther; 2008 May; 8(5):707-16. PubMed ID: 18471044
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of irinotecan in colorectal cancer.
    Saltz LB
    Curr Oncol Rep; 1999; 1(2):155-60. PubMed ID: 11122813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical development of 9-aminocamptothecin.
    Takimoto CH; Thomas R
    Ann N Y Acad Sci; 2000; 922():224-36. PubMed ID: 11193898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
    Keshelava N; Groshen S; Reynolds CP
    Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.
    Sato T; Hatate K; Ikeda A; Yamanashi T; Ozawa H; Onosato W; Nakamura T; Ihara A; Watanabe M
    Expert Opin Pharmacother; 2008 May; 9(7):1223-8. PubMed ID: 18422478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical use of topoisomerase I inhibitors in anticancer treatment.
    Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
    Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of topoisomerase I inhibitors in small-cell lung cancer.
    Fukuoka M
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):9-13. PubMed ID: 11497234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
    Lamond JP; Mehta MP; Boothman DA
    J Neurooncol; 1996 Oct; 30(1):1-6. PubMed ID: 8864997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Colorectal cancer chemotherapy: irinotecan.
    Rougier P; Mitry E
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):138-43. PubMed ID: 11049046
    [No Abstract]   [Full Text] [Related]  

  • 53. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
    Lavergne O; Bigg DC
    Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Evaluation of quality of life in patients with advanced colorectal cancer treated with topotecan].
    Foltyn W; Ziółko E; Danikiewicz A; Knopik J; Bucior J; Jastrzebska-Okoń K; Nowakowska-Zajdel E; Brodziak A
    Pol Merkur Lekarski; 2001 Mar; 10(57):145-7. PubMed ID: 11398512
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
    Goldberg RM; Erlichman C
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical activity spectrum of irinotecan].
    Cottu PH; Extra JM; Lerebours F; Espie M; Marty M
    Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapy for advanced colorectal cancer.
    Benson AB
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):2-11. PubMed ID: 9786311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Van Cutsem E; Peeters M
    Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
    Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
    Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.